Search clinical trials for: LY2886721

Total 7 results

Eli Lilly and Company

Terminated

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Alzheimer's Disease

United States, Italy, Japan, Spain, Netherlands
Eli Lilly and Company

Completed

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2886721 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

Alzheimer Disease | Healthy Volunteers

United States
Eli Lilly and Company

Completed

Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Safety Study of LY2886721 Single Doses in Healthy Subjects

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

Alzheimer's Disease

United States

3

Subscribe